Abstract brain with glowing electric fields, symbolizing innovative cancer treatment.

Brain Cancer Breakthroughs: Electric Fields and Personalized Medicine

Elliot Brynn monogram
Elliot Brynn in Health & Wellness November 2026 • 4 min read.

"Exploring the Latest Advancements in Glioblastoma Treatment and the Potential of Electric Field Therapies."


Glioblastoma multiforme (GBM) remains one of the most aggressive and challenging brain cancers to treat. Despite advances in surgery, radiation, and chemotherapy, the prognosis for patients with GBM is often poor, highlighting the urgent need for innovative therapeutic strategies.

Recent research has explored new avenues for GBM treatment, focusing on the use of electric fields to disrupt cancer cell growth and personalized medicine approaches to tailor therapies to individual patient characteristics. These advancements offer hope for improving outcomes and quality of life for individuals affected by this devastating disease.

This article delves into the latest breakthroughs in glioblastoma treatment, examining the potential of electric field therapies, the role of personalized medicine, and the ongoing efforts to enhance survivorship and address the educational needs of healthcare professionals involved in neuro-oncology care.

AI Search Multiple angles on this topic

U.S. Burden of Brain and Nervous System Cancer

SEER estimates that about 0.6% of men and women will be diagnosed with brain and other nervous system cancer during their lifetime, based on 2021–2023 data. In 2023, an estimated 196,343 people in the United States were living with these cancers. The listed glioblastoma fact sheet identifies the Central Brain Tumor Registry of the United States (CBTRUS) as its data source, combining data from the CDC’s National Program of Cancer Registries and the NCI’s Surveillance, Epidemiology, and End Results Program.

How Glioblastoma Came to Be Understood

The historical account describes the development of neurosurgery and neuropathology as essential first steps toward understanding glioblastoma. A history of glioma classification highlights how repositories of images and tissue samples supported the categorization of brain tumors and the development of glioblastoma treatments. Current understanding of glioblastoma’s origin remains incomplete: a 2023 review says its precise oncogenic mechanisms and glioma-initiating cell have yet to be identified, while recent studies have prompted the hypothesis that it may arise from neural stem cells or glial precursor cells.

Electric Field Therapy: A Novel Approach to Glioblastoma Treatment

Abstract brain with glowing electric fields, symbolizing innovative cancer treatment.

Tumor Treating Fields (TTFields) have emerged as a promising non-invasive therapy for glioblastoma, utilizing alternating electric fields to disrupt cancer cell division and proliferation. Clinical trials have demonstrated the potential of TTFields to improve survival rates in patients with both newly diagnosed and recurrent GBM.

A study presented at a recent neuro-oncology conference investigated the repurposing of deep brain stimulation (DBS) electrodes as a novel delivery method for therapeutic electric fields. Researchers found that delivering low-intensity, low-frequency electric fields via DBS electrodes had anti-proliferative effects on glioblastoma multiforme cell lines in vitro.

  • The study involved inserting Medtronic DBS electrodes into cell culture flasks and delivering electric fields over a range of voltages and frequencies to primary, adult, and pediatric GBM cell lines.
  • Cell viability, cell count, and cell cycle analyses were performed to assess the effects of electric field treatment on cancer cells.
  • Results showed that DBS electric fields negatively affected cell counts and viabilities of GBM cells, with cell viability reduced by up to 70% in U87 cells, 74% in SF188 cells, 71% in KNS42 cells, and 45% in GIN-5 cells.
  • Cell cycle analysis revealed that electrotreatment significantly increased the proportion of cells in the G0 phase, indicating cell cycle arrest.
AI Search Multiple angles on this topic

Recent Reviews of Glioblastoma Research

A 2024 review examines the updated state of glioblastoma research, describing the disease as an aggressive brain tumor with limited treatment options. A 2025 review explores its pathophysiology, molecular mechanisms, and therapeutic advances, and describes GBM as highly heterogeneous, with molecular subtypes tied to genetic and epigenetic alterations. A systematic review and meta-analysis published in 2026 compares bevacizumab-, temozolomide-, and lomustine-based treatments for recurrent glioblastoma.

Why Glioblastoma Treatment Remains Difficult

The sources describe treatment resistance and recurrence as persistent problems in glioblastoma, alongside challenges involving immune adaptation, metabolic reprogramming, and delivery across the blood–brain barrier. One review identifies surgery, radiation therapy, and temozolomide chemotherapy as the standard of care while examining why the disease remains difficult to treat. Another review attributes treatment failure to multiple factors, including tumor heterogeneity, cancer stem cells, and an immunosuppressive tumor microenvironment; a separate critical review considers resistant mechanisms and combination strategies as ways to address the limitations of monotherapies.

Incidence of Adult Malignant Primary Brain Tumors

A review reports an incidence of 3.5 per 100,000 population for glioblastoma. It identifies GBM as the most common malignant primary neoplasm of the brain in adults. The source provides this incidence figure but does not offer a comparison with other tumor types or treatments.

These findings suggest that implantable DBS electrodes could serve as a localized electric field-based therapeutic strategy for treating brain tumors, potentially addressing compliance issues associated with current TTFields delivery methods like Optune. Further research is needed to evaluate the efficacy and safety of this approach in clinical trials.

Looking Ahead: Improving Survivorship and Quality of Life

Ongoing research efforts are focused on improving survivorship and quality of life for patients with brain metastases. One study highlighted the importance of assessing and addressing the educational needs of non-neuro-oncology health professionals involved in the care of these patients. By providing targeted education and training, healthcare teams can enhance their ability to manage the complex needs of brain metastases patients and improve outcomes.

AI Search Multiple angles on this topic

Molecular and Immune Context for Future Research

An expert-opinion review reports that many bone marrow-derived macrophages are present in glioblastoma tumor tissue, while brain-resident microglia mostly appear around GBM tissues. It also describes single-cell sequencing of immune cells sorted from GBM samples using CD45 or CD11b antibodies, which revealed cell types, distribution, and transcriptomic features. A separate 2026 review says randomized controlled trials have evaluated multiple targeted therapies, but their results are inconsistent and lack systematic comparisons; it used network meta-analysis to examine them.

TTFields survival figures against standard chemotherapy

  • 4.9 monthsIn the EF-14 trial, median overall survival was 20.9 months with TTFields plus temozolomide, compared with 16 months with temozolomide alone—a difference of 4.9 months.[1]
  • 2.7 monthsMedian progression-free survival was 6.7 months with the combination and 4 months with temozolomide alone, a difference of 2.7 months.[1]
  • 5.2 monthsIn a 2023 meta-analysis of clinical-practice data, median overall survival was 22.6 months with standard care plus TTFields and 17.4 months with standard care alone, a difference of 5.2 months.[1]

How clinical evidence compares with device and treatment constraints

The EF-14 survival and progression-free-survival comparisons favor adding TTFields to temozolomide, while the clinical-practice meta-analysis also reports a survival difference favoring TTFields alongside standard care. Together, these findings point in the same direction, though they come from distinct forms of evidence.[1]

TTFields are described as alternating fields at 200 kHz that disrupt cell division; the fields within the brain are non-uniform and depend on tissue geometry and dielectric properties. That variability offers a possible explanation for why treatment outcomes differ, rather than showing that every brain receives the same field exposure.[1] [2] [3] [4]

The evidence base has design and synthesis constraints: some clinicians skeptical of EF-14 cited the absence of a sham device or concern that its results could be spurious, and an assessment could not pool randomized-trial outcomes because few trials existed and their populations differed. An independent device-controlled trial in a non-overlapping population was identified as a remaining evidence need.[5] [6]

A meta-analysis also found lower overall-survival risk among patients whose TTFields compliance was at least 75% of therapy time than among those below that level. This is an association within the analyzed data, not proof that compliance alone caused the difference.[7]

What evidence could clarify electric-field treatment

  • Would an independent trial with a sham device and a patient population that does not overlap EF-14 reproduce the clinical benefit?[5]
  • How much do variation in brain field distribution and differences between trial populations affect estimates of TTFields outcomes?[3] [6]
  • Would the survival effect seen with implanted-electrode dnEFT in mice also occur in people?[8]

Terms used in electric-field treatment research

Overall survival
OS[2]
Tumor Treating Fields
TTFields[2] [4]

Sources

  1. Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting (pmc.ncbi.nlm.nih.gov)
  2. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly di (pmc.ncbi.nlm.nih.gov)
  3. Predicting the electric field distribution in the brain for the treatment of glioblastoma. (pubmed.ncbi.nlm.nih.gov)
  4. Tumor treating fields: a novel treatment modality and its use in brain tumors (pmc.ncbi.nlm.nih.gov)
  5. Current usage of tumor treating fields for glioblastoma (pmc.ncbi.nlm.nih.gov)
  6. www.bag.admin.ch (www.bag.admin.ch)
  7. Dexamethasone and compliance affect TTFields efficacy to glioblastoma patients: a systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)
  8. Directionally non-rotating electric field therapy delivered through implanted electrodes as a glioblastoma treatment platform: A proof-of-principle study. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What are Tumor Treating Fields (TTFields), and how do they work against Glioblastoma Multiforme?

Tumor Treating Fields, or TTFields, is a non-invasive therapy that uses alternating electric fields to disrupt the division and growth of Glioblastoma Multiforme cells. These fields interfere with the cancer cells' ability to multiply, potentially slowing the progression of the disease. This approach differs significantly from traditional methods like chemotherapy and radiation by targeting the physical process of cell division.

2

How does personalized medicine change the landscape of Glioblastoma Multiforme treatment?

Personalized medicine in Glioblastoma Multiforme treatment tailors therapeutic strategies to the unique characteristics of each patient. This approach considers individual genetic and molecular profiles to select the most effective treatments, potentially improving outcomes and reducing side effects. Unlike a one-size-fits-all approach, personalized medicine aims to optimize treatment plans based on specific patient needs and responses.

3

What's the innovative approach of repurposing Deep Brain Stimulation (DBS) electrodes for Glioblastoma Multiforme therapy?

The repurposing of Deep Brain Stimulation electrodes for electric field therapy involves using existing DBS technology to deliver low-intensity, low-frequency electric fields directly to Glioblastoma Multiforme cells. Research indicates that these fields can have anti-proliferative effects, disrupting cancer cell growth. This method could offer a more localized and potentially more effective way to administer electric field therapy compared to existing methods.

4

What impact do Tumor Treating Fields and Deep Brain Stimulation-delivered electric fields have on Glioblastoma Multiforme cells, according to recent research?

Research indicates that Tumor Treating Fields and the use of Deep Brain Stimulation electrodes to deliver electric fields can negatively affect cell counts and viability of Glioblastoma Multiforme cells. Specifically, studies have shown significant reductions in cell viability and an increase in the proportion of cells in the G0 phase, indicating cell cycle arrest. The magnitude of these effects can vary depending on the Glioblastoma Multiforme cell line and the parameters of the electric field treatment.

5

Why is educating non-neuro-oncology health professionals important in managing Glioblastoma Multiforme, and what aspects require more attention?

The study on non-neuro-oncology health professionals highlights the critical need for targeted education and training to improve the care of patients. By enhancing the knowledge and skills of healthcare teams, patients receive better management of their complex needs, ultimately leading to improved outcomes and quality of life. Areas not covered included specialized training on specific treatment modalities like electric field therapy.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.